These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 39146783)

  • 1. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
    Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F
    Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
    Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
    Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Top advances of the year: Perioperative therapy for lung cancer.
    Aredo JV; Wakelee HA
    Cancer; 2024 Sep; 130(17):2897-2903. PubMed ID: 38717993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 5. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges.
    D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B
    Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
    Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immunotherapy in early-stage and metastatic NSCLC.
    Lieber A; Makai A; Orosz Z; Kardos T; Isaac SJ; Tornyi I; Bittner N
    Pathol Oncol Res; 2024; 30():1611713. PubMed ID: 39027681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
    Lochrin SE; Forde PM
    Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
    Han Y; Xiao X; Qin T; Yao S; Liu X; Feng Y; Li Z; Li Y; Xia S
    Cancer Immunol Immunother; 2024 Oct; 73(12):262. PubMed ID: 39382658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery.
    Jeon H; Gor R; D'Aiello A; Stiles B; Illei PB; Halmos B
    Pathol Oncol Res; 2024; 30():1611817. PubMed ID: 38957347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
    Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.
    Efil SC; Bilgin B; Ceylan F; Karakaş H; Karahan İ; Özsan SN; Kosku H; Yaman Ş; Bülent Akıncı M; Dede DŞ; Yalçın B; Nahit Şendur MA
    J Oncol Pharm Pract; 2024 Oct; 30(7):1214-1239. PubMed ID: 38860323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition in early-stage non-small cell lung cancer.
    Cuppens K; Du Pont B; Knegjens J; Maes B; Baas P
    Lung Cancer; 2024 Jul; 193():107855. PubMed ID: 38896941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.